CN117147841A - 尿液尿激酶纤溶酶原激活物及其多肽片段在系统性红斑狼疮中的应用 - Google Patents

尿液尿激酶纤溶酶原激活物及其多肽片段在系统性红斑狼疮中的应用 Download PDF

Info

Publication number
CN117147841A
CN117147841A CN202210241042.9A CN202210241042A CN117147841A CN 117147841 A CN117147841 A CN 117147841A CN 202210241042 A CN202210241042 A CN 202210241042A CN 117147841 A CN117147841 A CN 117147841A
Authority
CN
China
Prior art keywords
plasminogen activator
urokinase plasminogen
gly
leu
sle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210241042.9A
Other languages
English (en)
Inventor
张曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202210241042.9A priority Critical patent/CN117147841A/zh
Publication of CN117147841A publication Critical patent/CN117147841A/zh
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972Plasminogen activators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104Lupus erythematosus [SLE]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Electrochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供一种尿液尿激酶纤溶酶原激活物(Urokinase‑type plasminogen activator)及其多肽片段的应用,具体为尿液尿激酶纤溶酶原激活物及其多肽片段在制备用于系统性红斑狼疮(Systemic lupus erythematosus,SLE)诊断、鉴别诊断、病情程度与活动性判断、治疗效果评价、监测、预后评估及机理研究等应用。SLE是由自身免疫介导的,以免疫炎症为突出表现的弥漫性结缔组织病,多数呈隐匿起病,常累及机体多个系统。本发明通过研究证实,尿液尿激酶纤溶酶原激活物及其多肽片段在SLE活动期患者中表达下降。可用于SLE患者的各种目的应用检测。本发明发挥尿液标本获取无创、可大规模重复取样、保存方便的优势,利用尿液标本检测尿液尿激酶纤溶酶原激活物及其多肽片段。

Description

尿液尿激酶纤溶酶原激活物及其多肽片段在系统性红斑狼疮 中的应用
技术领域
本发明涉及尿液尿激酶纤溶酶原激活物及其多肽片段的新用途,具体涉及尿液尿激酶纤溶酶原激活物及其多肽片段在SLE诊断、鉴别诊断、病情程度与活动性判断、治疗效果评价、监测、预后评估及机理研究等应用。
背景技术
系统性红斑狼疮(systemic lupus erythematosus,SLE)是一种可累及全身多脏器的自身免疫性结缔组织疾病,好发于生育年龄女性。依据流行病学统计研究显示,我国SLE的患病率为70/10万人,妇女中则高达113/10万人。该病病因尚未十分明确,SLE常呈隐匿性起病,临床表现复杂多样,鼻梁和双颧颊部呈蝶形分布的红斑是SLE特征性的改变。SLE的皮肤损害还包括光敏感、脱发、手足掌面和甲周红斑、盘状红斑、雷诺现象等。除此之外,SLE病程发展还常涉及机体多个系统,尤其以重要脏器系统受累为著,如狼疮肾炎、神经精神狼疮、心包积液、血液及消化系统损害。可见,对于该病患者及时的诊断、有效的病情监测以及针对性的治疗尤为重要。
尿激酶纤溶酶原激活物(Urokinase-type plasminogen activator,uPA)属于丝氨酸蛋白酶类,其不仅可将无活性的纤溶酶原活化,降解细胞周围机制和基膜成分,还可启动细胞信号,通过整合素将细胞外信号传至细胞内,引起胞内蛋白酶类磷酸化。已有多个研究表明uPA在肿瘤的侵袭和转移中起重要作用,特别是与鼻咽癌的发生发展关系密切。本研究SLE活动期患者尿激酶纤溶酶原激活物在尿液中含量降低。
与常用的临床血液样本相比,尿液可以完全无创、连续、大量收集;没有稳态调节,可累积更多种类、更大幅度的变化,机体的很多病理生理变化可能体现在尿液中。一些激素和细胞因子等分子量相对较小的蛋白多肽入血后,会很快被排泄进入尿液,这些蛋白和多肽在尿液中被检测到的概率比在血中大很多;尿液收集之前,尿中可能的蛋白降解过程已经完成,所以尿蛋白可在较长时间内保持稳定。为减轻SLE患者多次采血的痛苦,本实验在前期方法学摸索的基础上,期望通过尿液蛋白或多肽研究,实现用无痛、方便、快捷、易重复的尿液检测辅助SLE患者的诊断及病情监测,也为进一步尿液多肽检测试剂盒的研究奠定基础。
发明内容
本发明的目的在于提供一种尿液尿激酶纤溶酶原激活物及其多肽片段在制备用于SLE诊断、鉴别诊断、病情程度与活动性判断、治疗效果评价、监测、预后评估及机理研究等的应用
优选地,所述尿液尿激酶纤溶酶原激活物的氨基酸序列包括SEQ ID NO.1所示(MRALLARLLL CVLVVSDSKG SNELHQVPSN CDCLNGGTCV SNKYFSNIHW CNCPKKFGGQ HCEIDKSKTCYEGNGHFYRG KASTDTMGRP CLPWNSATVL QQTYHAHRSD ALQLGLGKHN YCRNPDNRRR PWCYVQVGLKPLVQECMVHD CADGKKPSSP PEELKFQCGQ KTLRPRFKII GGEFTTIENQ PWFAAIYRRH RGGSVTYVCGGSLISPCWVI SATHCFIDYP KKEDYIVYLG RSRLNSNTQG EMKFEVENLI LHKDYSADTL AHHNDIALLKIRSKEGRCAQ PSRTIQTICL PSMYNDPQFG TSCEITGFGK ENSTDYLYPE QLKMTVVKLI SHRECQQPHY
YGSEVTTKML CAADPQWKTD SCQGDSGGPL VCSLQGRMTL TGIVSWGRGC ALKDKPGVYTRVSHFLPWIR SHTKEENGLA L)、SEQ ID NO.2所示(MVFHLRTRYE QANCDCLNGG TCVSNKYFSNIHWCNCPKKF GGQHCEIDKS KTCYEGNGHF YRGKASTDTM GRPCLPWNSA TVLQQTYHAH RSDALQLGLGKHNYCRNPDN RRRPWCYVQV GLKPLVQECM VHDCADGKKP SSPPEELKFQ CGQKTLRPRF KIIGGEFTTIENQPWFAAIY RRHRGGSVTY VCGGSLISPC WVISATHCFI DYPKKEDYIV YLGRSRLNSN TQGEMKFEVENLILHKDYSA DTLAHHNDIA LLKIRSKEGR CAQPSRTIQT ICLPSMYNDP QFGTSCEITG FGKENSTDYLYPEQLKMTVV KLISHRECQQ PHYYGSEVTT KMLCAADPQW KTDSCQGDSG GPLVCSLQGR MTLTGIVSWGRGCALKDKPG VYTRVSHFLP WIRSHTKEEN GLAL);或由SEQ ID NO:1~2所示的氨基酸序列衍生的,且与SEQ ID NO:1~2所示的氨基酸序列具有相同功能的氨基酸序列。
优选地,所述制剂为SLE患者尿液尿激酶纤溶酶原激活物及其多肽片段检测试剂盒。
优选地,所述试剂盒包括抗原抗体反应的免疫方法及其试剂盒如能够特异性结合尿激酶纤溶酶原激活物及其多肽片段的适配体抗体或抗体片段中的一种或多种。
优选地,所述检测方法包括直接检测尿激酶纤溶酶原激活物及其多肽片段的质谱等方法及其相关试剂盒。
优选地,所述检测方法包括直接检测尿激酶纤溶酶原激活物及其多肽片段的相关核酸检测等方法及其相关试剂盒。
优选地,所述试剂盒还包括选自下组的成分:固相载体,稀释液,对照品,标准品,质控品,检测抗体,第二抗体、第二抗体稀释液,发光试剂,洗涤液、显色液、终止液中的任意一种或几种的组合。
优选地,所述标准品包括尿激酶纤溶酶原激活物标准品、人源化标签抗体标准品;较佳地,所述质控品包括:尿激酶纤溶酶原激活物质控品、人源化标签抗体质控品;较佳地,所述固相载体包括:微粒、微球、玻片、试纸条、塑料珠、液相芯片、微孔板或亲和膜等以及同等功能的其他载体。
优选地,所述固相载体的材质为聚氯乙烯、聚苯乙烯、聚丙酰胺、纤维素中的任意一种及具有类似功能的载体。
发明人首先收集了健康人、SLE活动期患者(aSLE)和稳定期患者(sSLE)的尿液标本,4000r/min离心5min后,吸取上清,采用Bradford法测定提取的蛋白浓度,进行SDS-PAGE酶解。尿液样本的Label-free质谱分析由OrbitrapFusion型质谱完成。将SLE组和正常对照组在质谱中得到的数据进行定量计算。以蛋白表达量差异在1.5倍以上且经统计检验P<0.05作为参考标准筛选差异性多肽。然后发明人对具有统计学意义的差异性多肽进行鉴定,利用数据库检索得到差异蛋白尿激酶纤溶酶原激活物。发明人利用平行反应监测技术(PRM)对SLE患者和健康人尿液中的尿激酶纤溶酶原激活物及其含量进行了验证。
本发明通过研究证实尿激酶纤溶酶原激活物及其多肽片段在SLE活动期患者的尿液中呈低表达,与临床诊断有较好的一致性。从而提出检测尿液尿激酶纤溶酶原激活物及其多肽片段可用于SLE的辅助诊断或病情监测。
本发明发挥尿液标本获取无创、可大规模重复取样、保存方便的优势,利用尿液标本检测尿液尿激酶纤溶酶原激活物及其多肽片段。
为让本发明的上述和其它目的、特征和优点能更明显易懂,下文特举较佳实施例,并配合附图,作详细说明如下。
附图说明
图1是尿液尿激酶纤溶酶原激活物及其多肽片段在SLE患者及健康对照组中含量图。
具体实施方式
实施例1 尿液标本的收集与处理
选取SLE患者作为SLE组,选取同期健康体检者作为正常对照组。收集各组研究对象入院后的新鲜晨尿样本30ml,不能正常排尿者收集其早晨导尿管中尿液,置于干燥、洁净的容器内。将收集的尿液标本4000r/min离心5min后,吸取上清,每管2ml分装,-80℃冰箱保存。
实施例2 质谱分析和尿液多肽的筛选
对尿液样品蛋白提取,并对提取的蛋白浓度进行测定。尿液样本的质谱分析由OrbitrapFusion型质谱完成。将实验组和正常对照组在质谱中得到的数据进行定量计算。组间比较采用t-test进行差异分析,以蛋白表达量差异在1.5倍以上且经统计检验P<0.05作为参考标准筛选差异表达蛋白。
实施例3 差异多肽的鉴定及分析
使用的数据库为Uniprot_Homo数据库,产生的质谱原始文件采用MaxQuant软件处理,检索参数设置见表1。
实施例4 尿液尿激酶纤溶酶原激活物的验证
Label-free质谱分析结果显示尿激酶纤溶酶原激活物在SLE活动期患者的尿液中低表达,利用平行反应监测技术(PRM)对SLE患者和健康人尿液中的尿激酶纤溶酶原激活物及其含量验证结果与Label-free质谱分析结果一致,如图1所示。尿激酶纤溶酶原激活物在各组间表达具有显著性差异。
虽然本发明已以较佳实施例披露如上,然其并非用以限定本发明,任何所属技术领域的技术人员,在不脱离本发明的精神和范围内,当可作些许的更动与改进,因此本发明的保护范围当视权利要求所界定者为准。
序列表
<110> 张 曼
<120> 尿液尿激酶纤溶酶原激活物及其多肽片段在系统性红斑狼疮中的应用
<130> 22PUPA -CN
<140> 22PUPA -CN
<141> 2022-02-17
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 431
<212> PRT
<213> Human Urine
<400> 1
Met Arg Ala Leu Leu Ala Arg Leu Leu Leu Cys Val Leu Val Val Ser
1 5 10 15
Asp Ser Lys Gly Ser Asn Glu Leu His Gln Val Pro Ser Asn Cys Asp
20 25 30
Cys Leu Asn Gly Gly Thr Cys Val Ser Asn Lys Tyr Phe Ser Asn Ile
35 40 45
His Trp Cys Asn Cys Pro Lys Lys Phe Gly Gly Gln His Cys Glu Ile
50 55 60
Asp Lys Ser Lys Thr Cys Tyr Glu Gly Asn Gly His Phe Tyr Arg Gly
65 70 75 80
Lys Ala Ser Thr Asp Thr Met Gly Arg Pro Cys Leu Pro Trp Asn Ser
85 90 95
Ala Thr Val Leu Gln Gln Thr Tyr His Ala His Arg Ser Asp Ala Leu
100 105 110
Gln Leu Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Asn Arg
115 120 125
Arg Arg Pro Trp Cys Tyr Val Gln Val Gly Leu Lys Pro Leu Val Gln
130 135 140
Glu Cys Met Val His Asp Cys Ala Asp Gly Lys Lys Pro Ser Ser Pro
145 150 155 160
Pro Glu Glu Leu Lys Phe Gln Cys Gly Gln Lys Thr Leu Arg Pro Arg
165 170 175
Phe Lys Ile Ile Gly Gly Glu Phe Thr Thr Ile Glu Asn Gln Pro Trp
180 185 190
Phe Ala Ala Ile Tyr Arg Arg His Arg Gly Gly Ser Val Thr Tyr Val
195 200 205
Cys Gly Gly Ser Leu Ile Ser Pro Cys Trp Val Ile Ser Ala Thr His
210 215 220
Cys Phe Ile Asp Tyr Pro Lys Lys Glu Asp Tyr Ile Val Tyr Leu Gly
225 230 235 240
Arg Ser Arg Leu Asn Ser Asn Thr Gln Gly Glu Met Lys Phe Glu Val
245 250 255
Glu Asn Leu Ile Leu His Lys Asp Tyr Ser Ala Asp Thr Leu Ala His
260 265 270
His Asn Asp Ile Ala Leu Leu Lys Ile Arg Ser Lys Glu Gly Arg Cys
275 280 285
Ala Gln Pro Ser Arg Thr Ile Gln Thr Ile Cys Leu Pro Ser Met Tyr
290 295 300
Asn Asp Pro Gln Phe Gly Thr Ser Cys Glu Ile Thr Gly Phe Gly Lys
305 310 315 320
Glu Asn Ser Thr Asp Tyr Leu Tyr Pro Glu Gln Leu Lys Met Thr Val
325 330 335
Val Lys Leu Ile Ser His Arg Glu Cys Gln Gln Pro His Tyr Tyr Gly
340 345 350
Ser Glu Val Thr Thr Lys Met Leu Cys Ala Ala Asp Pro Gln Trp Lys
355 360 365
Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Ser Leu
370 375 380
Gln Gly Arg Met Thr Leu Thr Gly Ile Val Ser Trp Gly Arg Gly Cys
385 390 395 400
Ala Leu Lys Asp Lys Pro Gly Val Tyr Thr Arg Val Ser His Phe Leu
405 410 415
Pro Trp Ile Arg Ser His Thr Lys Glu Glu Asn Gly Leu Ala Leu
420 425 430
<210> 2
<211> 414
<212> PRT
<213> Human Urine
<400> 2
Met Val Phe His Leu Arg Thr Arg Tyr Glu Gln Ala Asn Cys Asp Cys
1 5 10 15
Leu Asn Gly Gly Thr Cys Val Ser Asn Lys Tyr Phe Ser Asn Ile His
20 25 30
Trp Cys Asn Cys Pro Lys Lys Phe Gly Gly Gln His Cys Glu Ile Asp
35 40 45
Lys Ser Lys Thr Cys Tyr Glu Gly Asn Gly His Phe Tyr Arg Gly Lys
50 55 60
Ala Ser Thr Asp Thr Met Gly Arg Pro Cys Leu Pro Trp Asn Ser Ala
65 70 75 80
Thr Val Leu Gln Gln Thr Tyr His Ala His Arg Ser Asp Ala Leu Gln
85 90 95
Leu Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Asn Arg Arg
100 105 110
Arg Pro Trp Cys Tyr Val Gln Val Gly Leu Lys Pro Leu Val Gln Glu
115 120 125
Cys Met Val His Asp Cys Ala Asp Gly Lys Lys Pro Ser Ser Pro Pro
130 135 140
Glu Glu Leu Lys Phe Gln Cys Gly Gln Lys Thr Leu Arg Pro Arg Phe
145 150 155 160
Lys Ile Ile Gly Gly Glu Phe Thr Thr Ile Glu Asn Gln Pro Trp Phe
165 170 175
Ala Ala Ile Tyr Arg Arg His Arg Gly Gly Ser Val Thr Tyr Val Cys
180 185 190
Gly Gly Ser Leu Ile Ser Pro Cys Trp Val Ile Ser Ala Thr His Cys
195 200 205
Phe Ile Asp Tyr Pro Lys Lys Glu Asp Tyr Ile Val Tyr Leu Gly Arg
210 215 220
Ser Arg Leu Asn Ser Asn Thr Gln Gly Glu Met Lys Phe Glu Val Glu
225 230 235 240
Asn Leu Ile Leu His Lys Asp Tyr Ser Ala Asp Thr Leu Ala His His
245 250 255
Asn Asp Ile Ala Leu Leu Lys Ile Arg Ser Lys Glu Gly Arg Cys Ala
260 265 270
Gln Pro Ser Arg Thr Ile Gln Thr Ile Cys Leu Pro Ser Met Tyr Asn
275 280 285
Asp Pro Gln Phe Gly Thr Ser Cys Glu Ile Thr Gly Phe Gly Lys Glu
290 295 300
Asn Ser Thr Asp Tyr Leu Tyr Pro Glu Gln Leu Lys Met Thr Val Val
305 310 315 320
Lys Leu Ile Ser His Arg Glu Cys Gln Gln Pro His Tyr Tyr Gly Ser
325 330 335
Glu Val Thr Thr Lys Met Leu Cys Ala Ala Asp Pro Gln Trp Lys Thr
340 345 350
Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Ser Leu Gln
355 360 365
Gly Arg Met Thr Leu Thr Gly Ile Val Ser Trp Gly Arg Gly Cys Ala
370 375 380
Leu Lys Asp Lys Pro Gly Val Tyr Thr Arg Val Ser His Phe Leu Pro
385 390 395 400
Trp Ile Arg Ser His Thr Lys Glu Glu Asn Gly Leu Ala Leu
405 410

Claims (9)

1.尿液尿激酶纤溶酶原激活物及其多肽片段在制备用于SLE诊断、鉴别诊断、病情程度与活动性判断、治疗效果评价、监测、预后评估及机理研究等的应用。
2.根据权利要求1所述的应用,其特征在于,所述尿液尿激酶纤溶酶原激活物的氨基酸序列包括SEQ ID NO:1~2所示;或由SEQ ID NO:1~2所示的氨基酸序列衍生的,且与SEQ IDNO:1~2所示的氨基酸序列具有相同功能的氨基酸序列。
3.根据权利要求1所述的应用,其特征在于,所述制剂为SLE患者尿液尿激酶纤溶酶原激活物及其多肽片段检测试剂盒。
4.根据权利要求3所述的应用,其特征在于,所述试剂盒包括抗原抗体反应的免疫方法及其试剂盒如能够特异性结合尿激酶纤溶酶原激活物及其多肽片段的适配体抗体或抗体片段中的一种或多种。
5.根据权利要求3所述的应用,其特征在于,所述检测方法包括直接检测尿激酶纤溶酶原激活物及其多肽片段的质谱等方法及其相关试剂盒。
6.根据权利要求3所述的应用,其特征在于,所述检测方法包括直接检测尿激酶纤溶酶原激活物及其多肽片段或其相关核酸检测等方法及其相关试剂盒。
7.根据权利要求3所述的应用,其特征在于,所述试剂盒还包括选自下组的成分:固相载体,稀释液,对照品,标准品,质控品,检测抗体,第二抗体、第二抗体稀释液,发光试剂,洗涤液、显色液、终止液中的任意一种或几种的组合。
8.根据权利要求7所述的应用,其特征在于,所述标准品包括尿激酶纤溶酶原激活物标准品、人源化标签抗体标准品;较佳地,所述质控品包括:尿激酶纤溶酶原激活物控品、人源化标签抗体质控品;较佳地,所述固相载体包括:微粒、微球、玻片、试纸条、塑料珠、液相芯片、微孔板或亲和膜等以及同等功能的其他载体。
9.根据权利要求8所述的应用,其特征在于,所述固相载体的材质为聚氯乙烯、聚苯乙烯、聚丙酰胺、纤维素中的任意一种及具有类似功能的载体。
CN202210241042.9A 2022-03-13 2022-03-13 尿液尿激酶纤溶酶原激活物及其多肽片段在系统性红斑狼疮中的应用 Pending CN117147841A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210241042.9A CN117147841A (zh) 2022-03-13 2022-03-13 尿液尿激酶纤溶酶原激活物及其多肽片段在系统性红斑狼疮中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210241042.9A CN117147841A (zh) 2022-03-13 2022-03-13 尿液尿激酶纤溶酶原激活物及其多肽片段在系统性红斑狼疮中的应用

Publications (1)

Publication Number Publication Date
CN117147841A true CN117147841A (zh) 2023-12-01

Family

ID=88906683

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210241042.9A Pending CN117147841A (zh) 2022-03-13 2022-03-13 尿液尿激酶纤溶酶原激活物及其多肽片段在系统性红斑狼疮中的应用

Country Status (1)

Country Link
CN (1) CN117147841A (zh)

Similar Documents

Publication Publication Date Title
CN117147841A (zh) 尿液尿激酶纤溶酶原激活物及其多肽片段在系统性红斑狼疮中的应用
CN117147863A (zh) 尿液丝氨酸蛋白酶抑制剂及其多肽片段在系统性红斑狼疮中的应用
CN117147842A (zh) 尿液凝血因子ix及其多肽片段在系统性红斑狼疮中的应用
CN117147860A (zh) 尿液肝素辅助因子ii及其多肽片段在系统性红斑狼疮中的应用
CN117233396A (zh) 尿液细胞外基质蛋白1及其多肽片段在系统性红斑狼疮中的应用
CN113777314A (zh) 尿液踝蛋白1及其多肽片段在烧伤中的应用
CN117147861A (zh) 尿液α-胰蛋白酶抑制剂重链H2及其多肽片段在系统性红斑狼疮中的应用
CN116794315A (zh) 尿液α-胰蛋白酶抑制剂重链H4及其多肽片段在系统性红斑狼疮中的应用
CN117147862A (zh) 尿液α-胰蛋白酶抑制剂重链H3及其多肽片段在系统性红斑狼疮中的应用
CN114113640A (zh) 尿液凝血因子ix及其多肽片段在烧伤中的应用
CN117147847A (zh) 尿液免疫球蛋白κ轻链及其多肽片段在系统性红斑狼疮中的应用
CN117147852A (zh) 尿液角蛋白i型细胞骨架18及其多肽片段在过敏性疾病中的应用
CN113777304A (zh) 尿液纤维蛋白溶解酶原及其多肽片段在烧伤中的应用
CN117147839A (zh) 尿液谷胱甘肽S-转移酶Omega-1及其多肽片段在过敏性疾病中的应用
CN113777313A (zh) 尿液维生素k依赖性蛋白s及其多肽片段在烧伤中的应用
CN115201482A (zh) 尿液免疫球蛋白λ轻链及其多肽片段在系统性红斑狼疮中的应用
CN117147856A (zh) 尿液白细胞介素4受体a及其多肽片段在过敏性疾病中的应用
CN117147857A (zh) 尿液白介素18及其多肽片段在过敏性疾病中的应用
CN113777303A (zh) 尿液凝血酶原及其多肽片段在烧伤中的应用
CN117147854A (zh) 尿液α1-抗胰蛋白酶及其多肽片段在过敏性疾病中的应用
CN117147858A (zh) 尿液低亲和力免疫球蛋白γFc区受体III-A及其多肽片段在过敏性疾病中的应用
CN114252603A (zh) 尿液过氧化氢酶及其多肽片段在过敏性疾病中的应用
CN117147840A (zh) 尿液谷胱甘肽s-转移酶a1及其多肽片段在过敏性疾病中的应用
CN117147855A (zh) 尿液低亲和力免疫球蛋白γFc区受体II-C及其多肽片段在过敏性疾病中的应用
CN113820485A (zh) 尿液碳酸酐酶3及其多肽片段在烧伤中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication